Publications by authors named "J Ishida"
Background/aim: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment.
View Article and Find Full Text PDFObjective: The extent of resection (EOR) is an important prognostic factor for both low- and high-grade gliomas. Intraoperative MRI (iMRI) has been used to increase the EOR in glioma surgery. While a recent study reported differences between iMRI and early postoperative MRI (epMRI), their specific relationship to postoperative clinical symptoms remains unclear.
View Article and Find Full Text PDFPortal annular pancreas (PAP) is an uncommon anomaly in which the pancreatic parenchyma surrounds the portal or superior mesenteric vein. An adequate operative approach is necessary to prevent clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy for PAP. We herein report a case of robotic pancreaticoduodenectomy for PAP.
View Article and Find Full Text PDFArticle Synopsis
- Around 5-10% of pancreatic cancer patients don't express CA 19-9, and it's unclear how this affects their cancer severity and prognosis.
- A study analyzed data from 88,749 pancreatic cancer patients, finding that non-expressors had a higher chance of distant metastasis and a shorter median overall survival compared to those with normal CA 19-9 levels.
- The findings suggest that patients who are non-expressors of CA 19-9 might need different diagnostic approaches and more aggressive treatment strategies.